UCB to Buy Candid Therapeutics for Up to $2.2 Billion
The deal seeks to bolster the company’s pipeline of experimental treatments for autoimmune and inflammatory diseases.
Connecting Global Economies
The deal seeks to bolster the company’s pipeline of experimental treatments for autoimmune and inflammatory diseases.